Category : Seeking Alpha

Category : Seeking Alpha

BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastro

Adverse events were generally low-grade, transient, and readily manageable

BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastro

Adverse events were generally low-grade, transient, and readily manageable

BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastro

Adverse events were generally low-grade, transient, and readily manageable

BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastro

Adverse events were generally low-grade, transient, and readily manageable

BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastro

Adverse events were generally low-grade, transient, and readily manageable

BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastro

Adverse events were generally low-grade, transient, and readily manageable

BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastro

Adverse events were generally low-grade, transient, and readily manageable

BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastro

Adverse events were generally low-grade, transient, and readily manageable

BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastro

Adverse events were generally low-grade, transient, and readily manageable

BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastro

Adverse events were generally low-grade, transient, and readily manageable

BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastro

Adverse events were generally low-grade, transient, and readily manageable

BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastro

Adverse events were generally low-grade, transient, and readily manageable

Nová biela kniha skúma budúcnosť platieb a vzostup platobnej siete štvrtej generácie

SINGAPUR, 3. júla 2025 /PRNewswire/ – Práve vydaná prelomová biela kniha s názvom The Future of Global Payments & Fourth Generation Payment Networks (4GPN) udáva tón novej ére v odvetví fintech. V dokumente, ktorý spoločne vypracovali Thunderbird...

Blue Sky Hemp Ventures Sells Hemp Food Division to Fresh Hemp Foods to Focus on Cannabis Extracts and Contract Manufacturing

SASKATOON, SK, July 3, 2025 /PRNewswire/ - Blue Sky Hemp Ventures Ltd. ("Blue Sky"), a privately held Canadian company founded in 2017 and a pioneer in industrial hemp whole plant utilization, has sold its hemp-based food division to Fresh Hemp Foods...

HL

LAWRENCE, Kan., July 3, 2025 /PRNewswire/ -- Prominently featured in The Inner Circle, Steven L. McCabe, PhD is acknowledged as a Pinnacle Lifetime Member for his contributions in Leading Government Engineering Efforts. Steven L. McCabe, PhD, brings...

«
1
2
...
11
12
13
14
15
16
17
...
58
59
»